The Emerging Role of IL-1 Inhibition in Patients Affected by Rheumatoid Arthritis and Diabetes

Author(s): Piero Ruscitti*, Paola Cipriani, Vasiliky Liakouli, Francesco Carubbi, Onorina Berardicurti, Paola Di Benedetto, Francesco Ciccia, Giuliana Guggino, Saverio Alvaro, Giovanni Triolo, Roberto Giacomelli.

Journal Name: Reviews on Recent Clinical Trials

Volume 13 , Issue 3 , 2018

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Although in the past, prevention of the joint destruction and disability was strongly emphasised in Rheumatoid Arthritis (RA), at present, a growing body of evidence is focused at identifying the best management of associated comorbidities, such as Type 2 Diabetes (T2D). Recently, the hypothesis that blocking pro-inflammatory activity may be helpful in the treatment of some comorbidities has been proposed in RA patients.

Objective: We reviewed the role of IL-1β during RA and T2D, the efficacy of IL-1 blocking agents in controlling both diseases and, possible, decreasing the concomitant enhanced atherosclerotic process.

Method: After literature search, the available evidence has been selected and commented in the text.

Results: During RA, it is well known that different inflammatory cytokines, such as interleukin-1β (IL-1β), are pivotal pathogenic mediators and their role has been largely confirmed in clinical settings. Similarly, it has been shown that the excess of nutrients, secondary to over-nutrition, may activate the immune system, leading to an increased production of inflammatory cytokines, including IL-1β, suggesting new possible therapeutic targets.

Conclusion: Although further studies are needed to fully investigate the pathogenic interplay between inflammation and metabolic disorders, IL-1β has been implicated in both RA and T2D pathogenic mechanisms. Intriguingly, the potential role of anti-IL-1 drugs has been proposed in RA patients affected by T2D.

Keywords: Anakinra, cardiovascular risk, diabetes, IL-1β, pathogenesis, rheumatoid arthritis, therapy.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 13
ISSUE: 3
Year: 2018
Page: [210 - 214]
Pages: 5
DOI: 10.2174/1574887113666180314102651
Price: $58

Article Metrics

PDF: 22
HTML: 3